Patent Leaderboard
USPTO Patent Rankings Data through Dec 31, 2025
Home › Selective EP4 receptor antagonistic substance for treatment of cancer

Selective EP4 receptor antagonistic substance for treatment of cancer

US Patent 11840530 · Granted Dec 12, 2023

Assignee

Inventors

View full patent text on Google Patents →

More Patents by These Inventors

Uses of benzimidazole derivative for nocturnal acid breakthrough2021
EP4 inhibitors and use thereof2021
EP4 inhibitors and use thereof2021
Ghrelin receptor agonist for treatment of cachexia2021
Selective EP4 receptor antagonistic substance for treatment of cancer2021
Selective EP4 receptor antagonistic substance for treatment of cancer2021
Selective EP4 receptor antagonistic substance for treatment of cancer2021
Selective EP4 receptor antagonistic substance for treatment of cancer2021
Use of EP4 receptor antagonists in the treatment of cartilage disease2020
Selective EP4 receptor antagonistic substance for treatment of cancer2020
Selective EP4 receptor antagonistic substance for treatment of cancer2020
Selective EP4 receptor antagonistic substance for treatment of cancer2020